Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly
Growth Hormone Deficiency
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Impact of Growth Hormone on Serum N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and on Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly|
- Changes in cardiac function i relation to changes in the activity of the GH-axis [ Designated as safety issue: No ]
|Study Start Date:||January 2006|
|Study Completion Date:||May 2009|
|Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
Patients with GHD
Pegvisomant and Somatostatin analogues
It is an open prospective noninterventional clinical study. Treatment and follow-up will be according to usual guidelines, and will be unaffected by inclusion in the study. GHD patients will be treated with daily subcutaneous GH injections. Patients with acromegaly will be treated with either transsphenoidal surgery or by medical treatment with long acting somatostatin analogues, dopamine agonist, GH antagonist or combinations of these treatment modalities.
Patients will be examined by Cardiac MRI before treatment and after one year of treatment.
No Contacts or Locations Provided